Abdourahmane Diallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdourahmane Diallo has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Eric Vicaut
AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7
6 shared publications - Gilles Montalescot
Sorbonne Université, ACTION Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
3 shared publications - Guillaume Cayla
Department of Cardiology, Nimes University Hospital, Montpellier University, ACTION Study Group , Nimes
2 shared publications - Géraldine Dray
Centre d’Assistance Médicale à la Procréation, Hôpital des Bluets, 4 Rue Lasson, 75012 Paris, France
2 shared publications - Johanne Silvain
Sorbonne Université, ACTION Study Group, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
2 shared publications - Laura Prat-Ellenberg
Centre d’Assistance Médicale à la Procréation, Hôpital des Bluets, 4 Rue Lasson, 75012 Paris, France
2 shared publications
Latest Publications
- Open Access
Differential Impact of the Endometrial Immune Environment in Fresh Versus Frozen Embryo Transfer
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prespecified secondary analysis of a prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBRs) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type-specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs. 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Precision care improved LBR compared with conventional management (48.6% vs. 14.7%; OR 5.03 [1.66–17.63]; ARD +33.9%). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant to implantation success after frozen embryo transfer and warrants confirmation in larger prospective studies.
Open AccessDifferential Impact of the Endometrial Immune Environment in Fresh Versus Frozen Embryo Transfer
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prespecified secondary analysis of a prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBRs) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type-specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs. 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Precision care improved LBR compared with conventional management (48.6% vs. 14.7%; OR 5.03 [1.66–17.63]; ARD +33.9%). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant to implantation success after frozen embryo transfer and warrants confirmation in larger prospective studies.
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
- 10 June 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (12) , 1056-1065
Heart Rate and Cardiovascular Outcomes in Post–Myocardial Infarction Patients Treated by β-Blockers: A Secondary Analysis of the ABYSS Trial
BACKGROUND: Heart rate (HR) is a key prognostic factor after myocardial infarction (MI), but its relevance in the modern reperfusion era is uncertain. We aim to evaluate the association between HR and β-blocker interruption on cardiovascular outcomes. METHODS: A prespecified secondary analysis of the ABYSS trial (Assessment of Beta-Blocker Interruption 1 Year After an Uncomplicted Myocardial Infarction), including 3698 stable post-MI patients (left ventricular ejection fraction ≥40%) randomized to continue or interrupt β-blockers, was conducted. Patients were grouped by prerandomization HR tertiles: P= 0.867). Higher HR was associated with increased risk of death, MI, or stroke (5.5% versus 6.4% versus 9.2%; P 50%). CONCLUSIONS: In stabilized post-MI patients with preserved ejection fraction, higher HR remains associated with adverse cardiovascular events and mortality in the reperfusion era. Interrupting β-blockers substantially increases HR and is consistently linked with worse outcomes irrespective of baseline HR, supporting continuation of β-blocker therapy.
- Open Access
- 2 June 2026
- Published by MDPI AG in Preprints.org
Differential Impact of the Endometrial Immune Environment in Fresh Versus Frozen Embryo Transfer
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBR) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type–specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Among dysregulated patients undergoing FET, precision care improved LBR compared with conventional management (48.6% vs 14.7%; OR 5.03 [1.66–17.63]). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant for optimizing implantation and live birth outcomes after frozen embryo transfer.
- 2 June 2026
- Published by MDPI AG in Preprints.org
Open AccessDifferential Impact of the Endometrial Immune Environment in Fresh Versus Frozen Embryo Transfer
Background: The endometrial immune environment regulates maternal immune tolerance and plays a key role in embryo implantation. We investigated whether its impact on reproductive outcomes differs between fresh and frozen embryo transfer (FET) cycles. Methods: In this prospective randomized study, 493 good-prognosis IVF patients underwent endometrial immune profiling before embryo transfer. Patients with a balanced profile received standard care, whereas those with immune dysregulation were randomized to conventional or immune-guided precision care. Live birth rates (LBR) were analyzed according to immune status, transfer type, and treatment strategy. Results: A transfer type–specific effect was observed. In FET cycles, a balanced immune profile was associated with higher LBR compared with immune dysregulation (52.4% vs 14.7%; adjusted OR 5.32 [95% CI 1.53–20.92]; ARD +37.7%). Among dysregulated patients undergoing FET, precision care improved LBR compared with conventional management (48.6% vs 14.7%; OR 5.03 [1.66–17.63]). No significant association between immune status and reproductive outcomes was observed in fresh transfers. Conclusions: The impact of the uterine immune environment differed according to embryo transfer type and was predominantly observed in FET cycles. These findings suggest that endometrial immune competence may be particularly relevant for optimizing implantation and live birth outcomes after frozen embryo transfer.
- 28 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (2) , e210194
Effect of Triheptanoin on Caudate Atrophy and Motor Scores in Patients With Early-Stage Huntington Disease
Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD. We conducted a 6-month bicentric (Paris, Leiden) double-blind randomized controlled trial followed by a 6-month open-label phase, between June 2015 and December 2019. We enrolled 107 patients at the early stage of HD-total motor score (TMS) of the UHDRS between 5 and 40. Participants received triheptanoin 1 g/kg/day or placebo (ratio 1/1). The primary outcome was the rate of caudate atrophy at 6 months using the caudate boundary shift integral (cBSI) method. Main secondary outcomes were cBSI at 12 months, TMS, and diffusion imaging at 6 and 12 months. Analysis was conducted using ANOVA, and data were presented with a 95% CI. To perform a 12-month comparison, we used the placebo arm of a 12-month randomized controlled trial conducted in parallel, using the double robust propensity score method. One hundred patients were randomized (mean age 49 years, 52% women). Fourteen patients withdrew from the study, including 10 because of gastrointestinal effects. There was no difference in cBSI at 6 months between groups (mean 0.026 [0.018-0.033] vs 0.023 [0.014-0.032]). TMS at 12 months was stable in patients treated with triheptanoin for 12 months (mean 0.6 [-1.1 to 2.1]), whereas it increased in patients initially on placebo (2.5 [1.2-3.8]). Compared with the external placebo control group, caudate atrophy decreased by approximately 50% (0.038 [0.028-0.048] vs 0.070 [0.057-0.082]) and TMS stabilized (0.66 [-1.07 to 2.48] vs 2.65 [1.38-3.89]) in patients treated with triheptanoin for 12 months. There was no effect of triheptanoin on caudate atrophy over 6 months. Compared with the external placebo group, triheptanoin was associated with motor stability and decreased caudate atrophy in patients treated for 12 months, but the post hoc nature of these findings is a major limitation. clinicaltrials.gov NCT02453061, May 25, 2015. First patient enrolled on June 29, 2015. This study provides Class I evidence that triheptanoin does not slow caudate atrophy compared with placebo over 6 months in patients with early HD.
- 28 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (2) , e210194
Effect of Triheptanoin on Caudate Atrophy and Motor Scores in Patients With Early-Stage Huntington Disease
Brain energy deficiency occurs at the early stage of Huntington disease (HD). Triheptanoin, a drug that targets the Krebs cycle, can restore a normal brain energetic profile in patients with HD. In this study, we aimed at assessing its efficacy on clinical and neuroimaging structural measures in HD. We conducted a 6-month bicentric (Paris, Leiden) double-blind randomized controlled trial followed by a 6-month open-label phase, between June 2015 and December 2019. We enrolled 107 patients at the early stage of HD-total motor score (TMS) of the UHDRS between 5 and 40. Participants received triheptanoin 1 g/kg/day or placebo (ratio 1/1). The primary outcome was the rate of caudate atrophy at 6 months using the caudate boundary shift integral (cBSI) method. Main secondary outcomes were cBSI at 12 months, TMS, and diffusion imaging at 6 and 12 months. Analysis was conducted using ANOVA, and data were presented with a 95% CI. To perform a 12-month comparison, we used the placebo arm of a 12-month randomized controlled trial conducted in parallel, using the double robust propensity score method. One hundred patients were randomized (mean age 49 years, 52% women). Fourteen patients withdrew from the study, including 10 because of gastrointestinal effects. There was no difference in cBSI at 6 months between groups (mean 0.026 [0.018-0.033] vs 0.023 [0.014-0.032]). TMS at 12 months was stable in patients treated with triheptanoin for 12 months (mean 0.6 [-1.1 to 2.1]), whereas it increased in patients initially on placebo (2.5 [1.2-3.8]). Compared with the external placebo control group, caudate atrophy decreased by approximately 50% (0.038 [0.028-0.048] vs 0.070 [0.057-0.082]) and TMS stabilized (0.66 [-1.07 to 2.48] vs 2.65 [1.38-3.89]) in patients treated with triheptanoin for 12 months. There was no effect of triheptanoin on caudate atrophy over 6 months. Compared with the external placebo group, triheptanoin was associated with motor stability and decreased caudate atrophy in patients treated for 12 months, but the post hoc nature of these findings is a major limitation. clinicaltrials.gov NCT02453061, May 25, 2015. First patient enrolled on June 29, 2015. This study provides Class I evidence that triheptanoin does not slow caudate atrophy compared with placebo over 6 months in patients with early HD.
- 19 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (21) , 1659-1668
Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial
BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. METHODS: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. RESULTS: A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, −12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, −2.9% [95% CI, −12.7% to 6.9%], and risk difference, −1.6% [95% CI, −11.8% to 8.6%], respectively). CONCLUSIONS: In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05213104.
- 19 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (21) , 1659-1668
Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial
BACKGROUND: The real incidence of atrial arrhythmia (AA) after patent foramen ovale (PFO) closure and whether this complication can be prevented remain unknown. We assessed whether flecainide is effective to prevent AA during the first 3 months after PFO closure, and whether 6 months of treatment with flecainide is more effective than 3 months to prevent AA after PFO closure. METHODS: AFLOAT (Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia Trial) is a prospective, multicentre, randomized, open-label, superiority trial with a blind evaluation of all the end points (PROBE [Prospective Randomized Open, Blinded End Point] design). Patients were randomized in a 1:1:1 ratio after PFO closure to receive flecainide (150 mg once daily in a sustained-release dose) for 3 months, flecainide (150 mg once daily in a sustained-release dose) for 6 months, or no additional treatment (standard of care) for 6 months. The primary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded within 3 months after PFO closure on long-term monitoring with an insertable cardiac monitor. The secondary end point was the percentage of patients with at least 1 episode of AA (≥30 seconds) recorded with insertable cardiac monitor during the 3- to 6-month period after PFO closure. RESULTS: A total of 186 patients were included (mean age, 54 years; 68.8% men) and AA (≥30 seconds) occurred in 53 patients (28.5%) during the 6-month follow-up; 86.8% of these AA events occurred in the first month after PFO closure. The primary outcome occurred in 33 of 123 (26.8%) and 16 of 63 (25.4%) patients receiving flecainide for at least 3 months or standard of care, respectively (risk difference, 1.4% [95% CI, −12.9% to 13.8%]; NS). The secondary end point occurred in 3 of 60 (5.0%), 4 of 63 (6.3%), and 5 of 63 (7.9%) patients receiving flecainide for 6 months, for 3 months, or standard of care, respectively (risk difference, −2.9% [95% CI, −12.7% to 6.9%], and risk difference, −1.6% [95% CI, −11.8% to 8.6%], respectively). CONCLUSIONS: In the first 6 months after successful PFO closure, AA (≥30 seconds) occurred in 28.5% of cases, mostly in the first month after the procedure. Flecainide did not prevent AA after PFO closure. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05213104.
- Open Access
- 28 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (21) , e26023
No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients
To assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10−3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10−3), with 82% of them older than 72 years vs only 23% of live patients (P < 10−3). Age (OR = 1.15; 95%CI = 1.04–1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7–80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.
- 28 May 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (21) , e26023
Open AccessNo evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients
To assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a matched case-control study from 3 French Hospital COVID-19 Departments, 27 patients with severe COVID-19 treated with TCZ and SOC were matched for baseline epidemiological and clinical features and compared to 27 severe COVID-19 patients treated with SOC alone. Baseline characteristics of the study population were comparable between groups. Eleven patients (20%) died. TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%), despite a higher decrease of the C-reactive protein at Day 7 (10.7 vs 52 mg/L; P < 10−3). Compared to the 43 patients alive at the end-of follow-up, patients who died were older (78 vs 64 years; P < 10−3), with 82% of them older than 72 years vs only 23% of live patients (P < 10−3). Age (OR = 1.15; 95%CI = 1.04–1.3; P = .008) and age over 72 years (OR) = 14.85; 95%CI = 2.7–80; P = .002) were independently associated with mortality. TCZ in addition to SOC for severe COVID-19 patients did not reduce mortality, subsequent need for invasive mechanical ventilation nor did it shorten the time of oxygen support, despite better control of the inflammatory response. More powerful and randomized controlled trials are warranted to determine if TCZ is effective in the management of COVID-19.
- Open Access
Lung injury in patients with or suspected COVID-19 : a comparison between lung ultrasound and chest CT-scanner severity assessments, an observational study
Background: Chest CT (CT) is the reference for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. We explored the role of lung ultrasonography (LU) in quickly assessing lung status in these patients. Methods: eChoVid is a multicentric study based on routinely collected data, conducted in 3 emergency units of Assistance Publique des Hôpitaux de Paris (APHP); 107 patients were included between March 19, 2020 and April 01, 2020 and underwent LU, a short clinical assessment by 2 emergency physicians blinded to each other’s and a CT. LU consisted of scoring lesions in 8 chest zones from 0 to 3, defining a severity global score (GS) ranging from 0 to 24. CT severity score ranged from 0 to 3 according to the extent of interstitial pneumonia signs. 48 patients underwent LU by both an expert and a newly trained physician. Findings: The GS showed good performance to predict CT severity assessment of COVID-19 as normal versus pathologic: AUC=0.93, maximal Youden index 1 with 95% sensitivity, and 83% specificity. Similar performance was found for CT assessment as normal or minimal versus moderate or severe (n=90): AUC 0.89, maximal Youden index 7 with 86% sensitivity, and 78% specificity. Good agreement was found for zone scoring assessed by new trainee (30mn theory + 30mn practice) and expert (n=14,14*8 checkpoints), weighted kappa 0.85-1; moderate agreement was found for new trainee (n=48, 30mn theory) and expert, kappa 0.62-0.81. Interpretation: GS score is a simple tool to assess lung damage severity in patients with suspected or diagnosed COVID-19. Comparing the performance of new trainees and expert physicians opens a path for adoption beyond the scope of experts. LU is a good candidate for patients triage, especially in case of CT availability issues.
Open AccessLung injury in patients with or suspected COVID-19 : a comparison between lung ultrasound and chest CT-scanner severity assessments, an observational study
Background: Chest CT (CT) is the reference for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. We explored the role of lung ultrasonography (LU) in quickly assessing lung status in these patients. Methods: eChoVid is a multicentric study based on routinely collected data, conducted in 3 emergency units of Assistance Publique des Hôpitaux de Paris (APHP); 107 patients were included between March 19, 2020 and April 01, 2020 and underwent LU, a short clinical assessment by 2 emergency physicians blinded to each other’s and a CT. LU consisted of scoring lesions in 8 chest zones from 0 to 3, defining a severity global score (GS) ranging from 0 to 24. CT severity score ranged from 0 to 3 according to the extent of interstitial pneumonia signs. 48 patients underwent LU by both an expert and a newly trained physician. Findings: The GS showed good performance to predict CT severity assessment of COVID-19 as normal versus pathologic: AUC=0.93, maximal Youden index 1 with 95% sensitivity, and 83% specificity. Similar performance was found for CT assessment as normal or minimal versus moderate or severe (n=90): AUC 0.89, maximal Youden index 7 with 86% sensitivity, and 78% specificity. Good agreement was found for zone scoring assessed by new trainee (30mn theory + 30mn practice) and expert (n=14,14*8 checkpoints), weighted kappa 0.85-1; moderate agreement was found for new trainee (n=48, 30mn theory) and expert, kappa 0.62-0.81. Interpretation: GS score is a simple tool to assess lung damage severity in patients with suspected or diagnosed COVID-19. Comparing the performance of new trainees and expert physicians opens a path for adoption beyond the scope of experts. LU is a good candidate for patients triage, especially in case of CT availability issues.
- 1 January 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 274, 337-341
Copeptin as a prognostic biomarker in acute myocardial infarction
- 1 January 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 274, 337-341
Copeptin as a prognostic biomarker in acute myocardial infarction